Skip to main navigation
skip to Main Content
Codexis
  • Why Codexis
    • Company
      • About Us
      • Why Codexis
      • Partners
      • Leadership
      • Board of Directors
    • Industries
      • Pharmaceuticals
      • Biotherapeutics
      • Food & Beverage
      • Molecular Diagnostics
    • Resources
      • Scientific Showcase
      • Awards & Recognition
      • News
      • Events
  • What You Need
    • Protein Engineering
    • CodeEvolver® Licensing
    • Scale-up and Supply
    • Screening Kits
  • Contact
  • Careers
  • Investors
Open Mobile Menu
Press Releases SEC Filings Stock Information Events / Webcasts Corporate Governance Analysts FAQ Contacts

Investors

SEC Filing Details

SEC Filing Details

Document Details

Form
4
Filing Date
Feb 7, 2018
Document Date
Feb 5, 2018
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Codexis, Inc
Issuer
CODEXIS INC

Filing Formats

View HTML
Download PDF
Download DOC
In This Section
  • Investors
  • Press Releases
  • SEC Filings
  • Stock Information
  • Events / Webcasts
  • Corporate Governance
  • Analysts
  • FAQ
  • Contacts
Recent News
  • February 14, 2019
    Summary ToggleCodexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
  • February 6, 2019
    Summary ToggleCodexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
  • February 4, 2019
    Summary ToggleCodexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
Featured Documents
Corporate Presentation 3 MB
Codexis Pipeline Snapshot 1.1 MB

Sign up for E-mail Alerts

 
Contact Investors Careers

© 2019 Codexis, Inc. All rights reserved. Privacy Policy Site Credits

Back To Top